MLYS
Price
$30.72
Change
-$0.84 (-2.66%)
Updated
Feb 4, 03:02 PM (EDT)
Capitalization
2.5B
42 days until earnings call
Intraday BUY SELL Signals
NMRA
Price
$1.96
Change
-$0.08 (-3.92%)
Updated
Feb 4, 03:05 PM (EDT)
Capitalization
345.82M
35 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

MLYS vs NMRA

Header iconMLYS vs NMRA Comparison
Open Charts MLYS vs NMRABanner chart's image
Mineralys Therapeutics
Price$30.72
Change-$0.84 (-2.66%)
Volume$100
Capitalization2.5B
Neumora Therapeutics
Price$1.96
Change-$0.08 (-3.92%)
Volume$255
Capitalization345.82M
MLYS vs NMRA Comparison Chart in %
MLYS
Daily Signal:
Gain/Loss:
NMRA
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
MLYS vs. NMRA commentary
Feb 05, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MLYS is a Hold and NMRA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 05, 2026
Stock price -- (MLYS: $31.56 vs. NMRA: $2.04)
Brand notoriety: MLYS and NMRA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MLYS: 136% vs. NMRA: 23%
Market capitalization -- MLYS: $2.5B vs. NMRA: $345.82M
MLYS [@Biotechnology] is valued at $2.5B. NMRA’s [@Biotechnology] market capitalization is $345.82M. The market cap for tickers in the [@Biotechnology] industry ranges from $118.13B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MLYS’s FA Score shows that 0 FA rating(s) are green whileNMRA’s FA Score has 1 green FA rating(s).

  • MLYS’s FA Score: 0 green, 5 red.
  • NMRA’s FA Score: 1 green, 4 red.
According to our system of comparison, MLYS is a better buy in the long-term than NMRA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MLYS’s TA Score shows that 4 TA indicator(s) are bullish while NMRA’s TA Score has 4 bullish TA indicator(s).

  • MLYS’s TA Score: 4 bullish, 3 bearish.
  • NMRA’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, MLYS is a better buy in the short-term than NMRA.

Price Growth

MLYS (@Biotechnology) experienced а -3.90% price change this week, while NMRA (@Biotechnology) price change was -4.23% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.56%. For the same industry, the average monthly price growth was +1.40%, and the average quarterly price growth was +33.10%.

Reported Earning Dates

MLYS is expected to report earnings on Mar 18, 2026.

NMRA is expected to report earnings on Mar 11, 2026.

Industries' Descriptions

@Biotechnology (-2.56% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MLYS($2.5B) has a higher market cap than NMRA($346M). NMRA YTD gains are higher at: 13.966 vs. MLYS (-13.034). MLYS has higher annual earnings (EBITDA): -184.03M vs. NMRA (-254.48M). MLYS has more cash in the bank: 594M vs. NMRA (172M). MLYS (0) and NMRA (0) have equivalent revenues.
MLYSNMRAMLYS / NMRA
Capitalization2.5B346M722%
EBITDA-184.03M-254.48M72%
Gain YTD-13.03413.966-93%
P/E RatioN/AN/A-
Revenue00-
Total Cash594M172M345%
Total DebtN/A20.1M-
TECHNICAL ANALYSIS
Technical Analysis
MLYSNMRA
RSI
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
74%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
89%
Advances
ODDS (%)
N/A
Bullish Trend 14 days ago
88%
Declines
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
64%
Bearish Trend 2 days ago
79%
Aroon
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
MLYS
Daily Signal:
Gain/Loss:
NMRA
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JUSSX19.680.04
+0.20%
JPMorgan US Small Company L
AFOIX20.45-0.07
-0.34%
Alger Mid Cap Focus I
AGVFX28.92-0.26
-0.89%
American Funds Global Insight A
FTWRX18.16-0.18
-0.98%
Templeton World R6
BCAMX74.55-0.95
-1.26%
Boston Common ESG Impact US Equity

MLYS and

Correlation & Price change

A.I.dvisor indicates that over the last year, MLYS has been loosely correlated with CYTK. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if MLYS jumps, then CYTK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MLYS
1D Price
Change %
MLYS100%
+2.24%
CYTK - MLYS
52%
Loosely correlated
-0.66%
IONS - MLYS
49%
Loosely correlated
+1.83%
NEVPF - MLYS
43%
Loosely correlated
N/A
PTGX - MLYS
38%
Loosely correlated
+3.06%
BIESF - MLYS
37%
Loosely correlated
N/A
More

NMRA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NMRA has been loosely correlated with VTYX. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if NMRA jumps, then VTYX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NMRA
1D Price
Change %
NMRA100%
+3.03%
VTYX - NMRA
41%
Loosely correlated
-0.07%
SNDX - NMRA
35%
Loosely correlated
-0.47%
LXRX - NMRA
33%
Loosely correlated
+2.40%
ADCT - NMRA
33%
Poorly correlated
N/A
MLYS - NMRA
32%
Poorly correlated
+2.24%
More